Equities research analysts predict that Oxford Immunotec Global PLC (NASDAQ:OXFD) will announce sales of $19.44 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Oxford Immunotec Global’s earnings. The lowest sales estimate is $19.18 million and the highest is $19.93 million. Oxford Immunotec Global reported sales of $29.32 million during the same quarter last year, which indicates a negative year over year growth rate of 33.7%. The business is scheduled to issue its next earnings report on Tuesday, July 30th.
According to Zacks, analysts expect that Oxford Immunotec Global will report full year sales of $70.41 million for the current financial year, with estimates ranging from $70.16 million to $70.58 million. For the next fiscal year, analysts anticipate that the business will report sales of $81.49 million, with estimates ranging from $79.32 million to $82.86 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that follow Oxford Immunotec Global.
Oxford Immunotec Global (NASDAQ:OXFD) last released its earnings results on Thursday, May 9th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.14. The business had revenue of $14.79 million for the quarter, compared to the consensus estimate of $13.74 million. Oxford Immunotec Global had a net margin of 172.27% and a return on equity of 13.56%. The firm’s quarterly revenue was up 26.6% compared to the same quarter last year. During the same period last year, the firm posted ($0.40) earnings per share.
Several research firms have recently weighed in on OXFD. BidaskClub downgraded shares of Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, June 26th. Zacks Investment Research downgraded shares of HEXO from a “hold” rating to a “sell” rating in a research report on Wednesday, May 15th. TheStreet downgraded shares of Viavi Solutions from a “b-” rating to a “c+” rating in a research report on Monday, June 3rd. Finally, ValuEngine raised shares of Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, April 1st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company. Oxford Immunotec Global presently has an average rating of “Hold” and a consensus price target of $18.00.
In related news, Director Richard A. Sandberg sold 3,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $16.05, for a total transaction of $48,150.00. Following the transaction, the director now directly owns 3,000 shares of the company’s stock, valued at $48,150. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 4.21% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of OXFD. FIL Ltd acquired a new stake in Oxford Immunotec Global in the first quarter valued at approximately $5,586,000. Martingale Asset Management L P acquired a new stake in shares of Oxford Immunotec Global in the fourth quarter worth $1,499,000. EAM Global Investors LLC acquired a new stake in shares of Oxford Immunotec Global in the first quarter worth $1,330,000. Marshall Wace LLP acquired a new stake in shares of Oxford Immunotec Global in the first quarter worth $1,185,000. Finally, Granite Investment Partners LLC acquired a new stake in shares of Oxford Immunotec Global in the first quarter worth $1,174,000. Hedge funds and other institutional investors own 91.57% of the company’s stock.
Shares of Oxford Immunotec Global stock traded down $0.16 during trading on Friday, hitting $13.31. The stock had a trading volume of 95,796 shares, compared to its average volume of 360,149. The stock’s 50 day simple moving average is $14.19. The stock has a market cap of $358.61 million, a P/E ratio of 26.10 and a beta of 0.35. The company has a quick ratio of 12.03, a current ratio of 12.60 and a debt-to-equity ratio of 0.04. Oxford Immunotec Global has a 1 year low of $11.66 and a 1 year high of $19.19.
Oxford Immunotec Global Company Profile
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.
Featured Story: What is diluted earnings per share (Diluted EPS)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.